Introduction
============

Gastric cancer (GC) is considered the third-leading cause of death among all cancer types and has caused 723,000 deaths across the whole world.[@b1-dddt-12-2173],[@b2-dddt-12-2173] Currently, the incidence of GC has been significantly increasing, with \~952,000 new cases each year.[@b2-dddt-12-2173] The People's Republic of China is a high-risk area for GC, and the new cases of GC in this region account for \~42.5% of such cases in the world.[@b3-dddt-12-2173] Early GC can easily be misdiagnosed because of the small number of symptoms. Most patients with GC have developed to an advanced stage or exhibited metastasis, and the 5-year survival rate is \<20% at this stage.[@b1-dddt-12-2173],[@b4-dddt-12-2173] Chemotherapy (CT) is one of the standard treatment regimens for advanced GC. Although CT improves patient survival, most patients eventually relapse and develop resistance to treatment, which is not able to completely eradicate small lesions and metastatic cells.[@b1-dddt-12-2173],[@b5-dddt-12-2173]--[@b7-dddt-12-2173] Thus, more effective and safer treatments are urgently required.

In recent years, the use of molecular targeted therapy has been increasing rapidly, and this approach is considered as a powerful therapeutic method for cancer treatment. The agents used in targeted therapy can precisely identify and attack certain type of cancer cells based on mutations of genes and proteins.[@b2-dddt-12-2173] Moreover, little damage is done to normal cells; thus, molecular targeted therapy is also called a "biological missile." The clinical application of molecular targeted therapy for malignancies has been reported, and several studies have found that the combination of molecular targeted therapy and CT has better therapeutic effects than treatment with CT alone.[@b8-dddt-12-2173]--[@b13-dddt-12-2173]

Angiogenesis is essential for tumor growth and metastasis, and VEGF and its receptors (VEGFRs) play a crucial role in angiogenesis.[@b14-dddt-12-2173]--[@b16-dddt-12-2173] VEGFR2 is one of 3 VEGFRs and plays a pivotal role in VEGF-mediated cancer angio-genesis.[@b17-dddt-12-2173] Apatinib is a novel antiangiogenic agent that specifically targets VEGFR2. This small molecule tyrosine kinase inhibitor was approved for the second-line treatment of advanced GC in the People's Republic of China in 2014.[@b17-dddt-12-2173],[@b18-dddt-12-2173] In several clinical trials, apatinib targeted therapy combined with CT exhibited more prominent therapeutic effects for advanced GC than CT alone.[@b19-dddt-12-2173]--[@b37-dddt-12-2173] However, systematic analyses assessing the therapeutic efficacy of apatinib targeted therapy combined with CT in advanced GC remain scarce. In this study, we conducted a meta-analysis to investigate the treatment effect and safety of apatinib targeted therapy combined with CT in comparison with CT alone for advanced GC to provide a scientific reference for the design of future clinical trials.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

The literature was searched across PubMed, the Cochrane Library, Web of Science, EMBASE, CNKI, and the Wanfang database with key terms "apatinib" combined with "gastric cancer." No language limits were applied. The initial search was performed in January 2018 and updated in March 2018.

Selection criteria: Studies concerning advanced GC patients were involved in our analysis. Patients in the experimental groups received apatinib targeted therapy combined with CT, and patients in the control group were treated with CT alone.

Data extraction and quality assessment
--------------------------------------

The data were independently extracted by 2 investigators (Honggang Cheng and Aixia Sun). Disagreements were resolved by discussion with a third researcher (Qingbo Guo). All involved studies were summarized as follows: the first author's name, year of publication, study location, tumor stages, number of cases, patient ages, study parameter types, therapeutic regimens, enrollment period, and dosages of apatinib utilized. The included trials' qualities were evaluated based on the Cochrane Handbook.[@b38-dddt-12-2173]

Outcome definition
------------------

The clinical responses included treatment efficacy, quality of life (QOL), and adverse events (AEs). Treatment efficacy was assessed in terms of the complete response rate (CR), partial response rate (PR), stable disease rate (SD), progressive disease rate (PD), overall response rate (ORR, ORR=CR+PR), and disease control rate (DCR, DCR=CR+PR+SD). The patients' QOLs were evaluated using the QOL improved rate (QIR) and the Karnofsky performance score (KPS). AEs, including leukopenia, thrombocytopenia, diarrhea, nausea and vomiting, hypertension, neutropenia, albuminuria, oral mucositis, hand--foot syndrome, weakness, hemoglobin reduction, and myelosuppression, were also assessed.

Statistical analysis
--------------------

The analyses were performed using Review Manager 5.3 (Cochrane Collaboration, London, UK). *P*\<0.05 was taken to indicate that the differences reached statistical significance. Heterogeneity among studies was assessed with the Cochran's *Q* test to determine the most suitable analysis model, and funnel plots were used to assess the publication biases of the involved studies.[@b39-dddt-12-2173] *I*[@b2-dddt-12-2173]\<50% or *P*\>0.1 indicated that a study was homogenous. The OR was the principal measurement of the therapeutic effects, and the ORs are presented with the 95% CIs. Sensitivity analyses were conducted to evaluate the influences of the therapeutic regimens, apatinib dosages, sample sizes, and types of involved studies.

Results
=======

Search results
--------------

A total of 476 articles were identified in the initial search. After review of the titles and abstracts, 384 articles were excluded because they did not include clinical trials (n=207), were unrelated studies (n=56), or were duplications or repetitions (n=121). This process left 92 studies as potentially relevant. After detailed assessment of the full texts, case reports and reviews (n=16), and articles without a control group (n=17) or without apatinib and CT combined therapy (n=23) or with insufficient data (n=4) were excluded. Finally, 19 trials[@b19-dddt-12-2173]--[@b37-dddt-12-2173] involving 1,256 advanced GC patients were included in this meta-analysis ([Figure 1](#f1-dddt-12-2173){ref-type="fig"}).

Patient characteristics
-----------------------

After selection, all of the included trials were conducted in the People's Republic of China. In total, 625 advanced GC patients were treated with apatinib in combination with CT, and 631 patients were treated with CT alone. Detailed information about the involved trials and patients is presented in [Tables 1](#t1-dddt-12-2173){ref-type="table"} and [2](#t2-dddt-12-2173){ref-type="table"}.

Quality assessment
------------------

The assessment of bias risk is presented in [Figure 2](#f2-dddt-12-2173){ref-type="fig"}. Fourteen studies were determined to be low risk, and the remaining 5 studies were not true randomized controlled trials. None of the included trials provided clear descriptions of the performance and detection risks. The attrition risks of the involved trials were low; 3 trials were considered to have unclear risk owing to selective reporting.

Therapeutic efficacy assessments
--------------------------------

As presented in [Figures 3](#f3-dddt-12-2173){ref-type="fig"} and [4](#f4-dddt-12-2173){ref-type="fig"}, [Figure S1](https://user.qzone.qq.com/1004136405/blog/1530667068), and [Table 3](#t3-dddt-12-2173){ref-type="table"}, the pooled results revealed that the patients who underwent combined therapy exhibited significantly improved CR, PR, ORR, and DCR (CR: OR=1.85, 95% CI=1.04--3.28, *P*=0.04; PR: OR=2.19, 95% CI=1.71--2.80, *P*\<0.00001; ORR: OR=2.57, 95% CI=1.99--3.32, *P*\<0.00001; DCR: OR=3.46, 95% CI=2.57--4.66, *P*\<0.00001) and significantly decreased PD (OR=0.33, 95% CI=0.25--0.44, *P*\<0.00001), whereas the SD was not significantly different from that of the patients who received CT alone (OR=1.09, 95% CI=0.86--1.39, *P*=0.48). Fixed effect models were used to analyze the OR rate because of low heterogeneity.

QOL assessment
--------------

QOL was evaluated in this analysis. The results revealed that the QOL of patients in the combined group was significantly better than that of the control group as indicated by the QIR and KPS, although the former did not reach significance ([Figure 5](#f5-dddt-12-2173){ref-type="fig"}, QIR: OR=1.77, 95% CI=0.94--3.33, *P*=0.08; KPS: OR=14.99, 95% CI=12.51--17.47, *P*\<0.00001).

AEs assessment
--------------

The safety of apatinib targeted therapy was evaluated in this meta-analysis. As presented in [Figure S2](https://user.qzone.qq.com/1004136405/blog/1530667068) and [Table 4](#t4-dddt-12-2173){ref-type="table"}, the group that received apatinib targeted therapy plus CT had higher rates of hypertension, albuminuria, and hand--foot syndrome (hypertension: OR=5.75, 95% CI=2.22--14.92, *P*=0.0003; albuminuria: OR=15.42, 95% CI=5.39--44.10, *P*\<0.00001; hand--foot syndrome: OR=2.09, 95% CI=1.26--3.48, *P*=0.004), whereas analyses of leukopenia, thrombocytopenia, diarrhea, nausea and vomiting, neutropenia, oral mucositis, weak, hemoglobin reduction, and myelosuppression did not reveal significant differences (leukopenia: OR=1.73, 95% CI=0.96--3.10, *P*=0.07; thrombocytopenia: OR=1.31, 95% CI=0.79--2.18, *P*=0.29; diarrhea: OR=0.63, 95% CI=0.36--1.10, *P*=0.10; nausea and vomiting: OR=1.02, 95% CI=0.71--1.46, *P*=0.92; neutropenia: OR=1.33, 95% CI=0.68--2.59, *P*=0.40; oral mucositis: OR=1.19, 95% CI=0.80--1.77, *P*=0.40; weak: OR=1.09, 95% CI=0.70--1.70, *P*=0.70; hemoglobin reduction: OR=2.13, 95% CI=0.69--6.59, *P*=0.19; myelosuppression: OR=0.96, 95% CI=0.57--1.63, *P*=0.89).

Publication bias
----------------

The funnel plots drawn for the studies of the primary outcomes (CR, PR, SD, PD, ORR, DCR, and AEs) were approximately symmetrical, which indicated the generally controlled publication bias and reliability of our primary conclusions ([Figures 6](#f6-dddt-12-2173){ref-type="fig"} and [S3](https://user.qzone.qq.com/1004136405/blog/1530667068) and [S4](https://user.qzone.qq.com/1004136405/blog/1530667068)).

Sensitivity analysis
--------------------

We conducted subgroup analyses to explore the sources of heterogeneity in the ORR and DCR with respect to therapeutic regimens, apatinib dosages, sample sizes, and types of involved studies. As presented in [Table 5](#t5-dddt-12-2173){ref-type="table"}, our analysis results revealed that no significant differences were found between the different therapeutic regimens, apatinib dosages, sample sizes, and types of studies.

Discussion
==========

In recent years, with the development of tumor molecular biology and epigenetics, increasing numbers of targeted agents, such as gefitinib, erlotinib, apatinib, etc, have been used to improve treatment effects for patients with malignancies.[@b40-dddt-12-2173]--[@b43-dddt-12-2173] As components of the important signaling pathway of cancer angiogenesis, VEGF and VEGFR are closely related to cancer invasiveness. Researchers have confirmed that the expressions of VEGF and VEGFR are associated with poor prognosis in GC.[@b44-dddt-12-2173],[@b45-dddt-12-2173] Upon binding to its receptors, the activated VEGF family promotes the proliferation of vascular cells for the development of new blood vessels in tumor tissues and then ensures oxygen and nutrient supplies and causes tumor growth and metastasis.[@b14-dddt-12-2173],[@b46-dddt-12-2173] Therefore, anti-VEGFR target drugs are considered promising prospects for the treatment of advanced GC.

The VEGFR family includes VEGFR-1, VEGFR-2, and VEGFR-3.[@b16-dddt-12-2173] Among these receptors, VEGFR2 plays an essential role in VEGF-mediated tumor angiogenesis.[@b14-dddt-12-2173],[@b17-dddt-12-2173] When it associates with VEGF, the dimerization of VEGFR2 causes the autophosphorylation of intracellular tyrosine kinase domains, which leads to the activation of the PLC-γ--Raf kinase--MEK--MAP kinase pathway, which in turn enhances endothelial cell proliferation.[@b14-dddt-12-2173],[@b15-dddt-12-2173] Apatinib is a new inhibitor of VEGFR-2 tyrosine kinase that targets the intracellular ATP binding site of the receptor.[@b17-dddt-12-2173] Several studies have reported that the addition of apatinib can be beneficial for patients with advanced GC.[@b42-dddt-12-2173],[@b43-dddt-12-2173] Although there are statistical analyses of published clinical trials, the exact therapeutic effects have not been systematically evaluated and demonstrated due to sample size variability among these trials. Additionally, the different applied protocols in the different clinical trials may have led to different therapeutic effects. In the present research, we performed an extensive online search followed by rigorous contrasting and combining data analyses in terms of categorization to provide a clear and systematical conclusion.

Our meta-analysis revealed that apatinib targeted therapy combined with CT is associated with a favorable efficacy compared with CT alone. Compared with the patients who were treated with CT alone, the patients who were treated with combined therapy exhibited markedly increased CR, PR, ORR, and DCR (*P*\<0.05). The patients' QOL was also evaluated in this analysis, and the QOL was significantly improved after combined therapy. These results indicated that apatinib targeted therapy increased the curative effect of CT by inhibiting tumor angiogenesis and thereby improving the patients' life qualities.

Safety is the top priority of clinical treatment, and it is also the key factor for the development of apatinib targeted therapy. Regarding AEs and severe toxicities, our analysis revealed that there were no significant differences in most of the AE indicators between the 2 groups. The group receiving CT plus apatinib targeted therapy had higher rates of hypertension, proteinuria, and hand--foot syndrome, which are usually controllable events and do not require permanent discontinuation of therapy.

Some factors may influence the therapeutic effects of apatinib targeted therapy. In our subgroup analysis, no differences were found between the different therapeutic regimens, apatinib dosages, sample sizes, and types of studies. However, currently published studies that have probed the influences of these factors on the curative effect of apatinib targeted therapy are still insufficient; thus, these issues should be further researched and explored. Furthermore, the determination of the optimal therapeutic strategy will be valuable for GC treatment. Recently, many novel treatment strategies, such as targeted therapy and immunotherapy, have been developed for the treatment of malignancies. Several studies have found that combined treatment with targeted therapy and immunotherapy for malignant tumors has better therapeutic effects than single therapy.[@b47-dddt-12-2173],[@b48-dddt-12-2173] Therefore, the combination of targeted therapy with an immunotherapy, such as chimeric antigen receptor-modified T cells, T-cell receptor-modified T cells, etc,[@b49-dddt-12-2173],[@b50-dddt-12-2173] may be the new direction for the future development of advanced GC treatment.

There are some limitations in our analysis. First, the number of GC patients included in this study is not sufficiently large, and the follow-up time was short. Apart from that, the different trials evaluated the treatment efficacy using different outcomes, so it was difficult to summarize the results on the same scale, which led to shrunken statistical sample sizes. Third, our data were partly extracted from published papers rather than original patient records, which mean that we were not able to avoid analytical bias based on the information presented in the articles. Due to the above limitations, future studies and generated data will be valuable to further verify the safety and efficacy of apatinib targeted therapy.

Conclusion
==========

In summary, our study confirmed that apatinib targeted therapy combined with CT is an effective treatment for advanced GC patients. Apatinib targeted therapy markedly enhances the treatment efficacy of CT for advanced GC. However, this combined treatment could lead to greater rates of hypertension, albuminuria, and hand--foot syndrome. Therefore, the benefits and risks should be considered before treatment.
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![Forest plot of the comparison of the ORR between the experimental and control group.\
**Notes:** Control group, CT alone group; experimental group, apatinib targeted therapy plus CT. The fixed effects meta-analysis model (Mantel--Haenszel method) was used.\
**Abbreviations:** CI, confidence interval; CT, chemotherapy; OR, odds ratio; ORR, overall response rate.](dddt-12-2173Fig3){#f3-dddt-12-2173}

![Forest plot of the comparison of the DCR between the experimental and control group.\
**Notes:** Control group, CT alone group; experimental group, apatinib targeted therapy plus CT. The fixed effects meta-analysis model (Mantel--Haenszel method) was used.\
**Abbreviations:** CI, confidence interval; CT, chemotherapy; DCR, disease control rate; OR, odds ratio.](dddt-12-2173Fig4){#f4-dddt-12-2173}

![Funnel plot of percentages of the ORR (**A**) and DCR (**B**) between the experimental and control groups.\
**Abbreviations:** CI, confidence interval; CT, chemotherapy; DCR, disease control rate; ORR, overall response rate.](dddt-12-2173Fig5){#f5-dddt-12-2173}

![Forest plot of the comparison of the QIR (**A**) and KPS (**B**) between the experimental and control groups.\
**Notes:** Control group, CT alone group; experimental group, apatinib targeted therapy plus CT. The fixed effects meta-analysis model (Mantel--Haenszel method) was used.\
**Abbreviations:** CI, confidence interval; CT, chemotherapy; KPS, Karnofsky performance score; QIR, quality of life improved rate.](dddt-12-2173Fig6){#f6-dddt-12-2173}

###### 

Clinical information from the eligible trials in the meta-analysis

  Included studies                       Nation                       Tumor stage    Patients Con/Exp   Age (year)         Parameter types    
  -------------------------------------- ---------------------------- -------------- ------------------ ------------------ ------------------ -------------------
  Dong et al,[@b19-dddt-12-2173] 2018    People's Republic of China   ND             41/41              ND                 ND                 ORR, DCR, KPS, AE
  Du,[@b20-dddt-12-2173] 2017            People's Republic of China   0--2 (ECOG)    40/40              54.6±10.4 (mean)   51.3±10.0 (mean)   ORR, DCR, AE
  Duan et al,[@b21-dddt-12-2173] 2017    People's Republic of China   III--IV        28/32              64.7±9.9 (mean)    63.2±9.5 (mean)    ORR, DCR, AE
  Fan et al,[@b22-dddt-12-2173] 2017     People's Republic of China   III--IV        15/15              ≥70 (1)            ≥70 (2)            ORR, DCR, QIR, AE
  Gao et al,[@b23-dddt-12-2173] 2017     People's Republic of China   60--80 (KPS)   15/16              ND                 ND                 ORR, DCR, AE
  Hu et al,[@b24-dddt-12-2173] 2016      People's Republic of China   ND             23/23              58.1±1.2 (mean)    57.8±1.1 (mean)    ORR, DCR, AE
  Jing,[@b25-dddt-12-2173] 2016          People's Republic of China   0--2 (ECOG)    21/21              75.1±3.7 (mean)    74.5±3.7 (mean)    ORR, DCR, AE
  Li et al,[@b26-dddt-12-2173] 2018      People's Republic of China   IV             30/34              55.5±9.5 (mean)    56.0±10.7 (mean)   ORR, DCR
  Li and Li,[@b27-dddt-12-2173] 2017     People's Republic of China   KPS ≥60        35/35              54.3±1.8 (mean)    55.6±1.5 (mean)    ORR, DCR, KPS
  Li,[@b28-dddt-12-2173] 2017            People's Republic of China   0--2 (ECOG)    20/20              48.0±11.5 (mean)   46.5±12.0 (mean)   ORR, DCR, AE
  Qian and Ge,[@b29-dddt-12-2173] 2017   People's Republic of China   IV             42/34              61 (median)        62 (median)        ORR, DCR, AE
  Sheng et al,[@b30-dddt-12-2173] 2017   People's Republic of China   III--IV        59/59              52.2±2.7 (mean)    51.4±2.6 (mean)    ORR, DCR, AE
  Wang et al,[@b31-dddt-12-2173] 2016    People's Republic of China   ND             29/29              58.6±12.0 (mean)   57.2±8.3 (mean)    ORR
  Wen et al,[@b32-dddt-12-2173] 2017     People's Republic of China   III--IV        45/45              62.9±4.3 (mean)    63.3±4.2 (mean)    ORR, DCR, AE
  Wu et al,[@b33-dddt-12-2173] 2017      People's Republic of China   III--IV        14/14              49.3±9.7 (mean)    48.9±9.8 (mean)    ORR, DCR, QIR, AE
  Yan et al,[@b34-dddt-12-2173] 2017     People's Republic of China   IV             75/75              56±6 (mean)        54±6 (mean)        ORR, DCR, AE
  Zhan,[@b35-dddt-12-2173] 2017          People's Republic of China   III--IV        40/40              63.7±3.4 (mean)    64.5±4.1 (mean)    ORR, DCR, QIR, AE
  Zhou et al,[@b36-dddt-12-2173] 2018    People's Republic of China   ND             20/20              61.1±9.5 (mean)    60.2±8.7 (mean)    ORR, DCR, QIR, AE
  Zhu et al,[@b37-dddt-12-2173] 2016     People's Republic of China   0--2 (ECOG)    39/32              60 (median)        56 (median)        ORR, DCR, AE

**Notes:** Con, control group (CT alone group); Exp, experimental group (apatinib targeted therapy plus CT).

**Abbreviations:** AE, adverse events; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group score; DCR, disease control rate; KPS, Karnofsky performance score; ND, nondetermined; ORR, overall response rate; QIR, quality of life improved rate.

###### 

Information of apatinib targeted therapy combined with CT

  Included studies                       Therapeutic regimen                        Line                              Enrollment period   Dosage of apatinib   
  -------------------------------------- ------------------------------------------ --------------------------------- ------------------- -------------------- ----------------------------
  Dong et al,[@b19-dddt-12-2173] 2018    Oxaliplatin+apatinib                       Oxaliplatin                       ND                  2013.1--2013.12      850 mg/time, 3 times/d
  Du,[@b20-dddt-12-2173] 2017            FBC+apatinib                               Fluorouracil                      ND                  2015.3--2017.4       500 mg/time, 1 time/d
  Duan et al,[@b21-dddt-12-2173] 2017    FOLFOX+apatinib                            FOLFOX                            ND                  2015.1--2016.12      850 mg/time, 1 time/d
  Fan et al,[@b22-dddt-12-2173] 2017     S-1+apatinib                               S-1                               I                   2015.1--2016.1       500 mg/time, 1 time/d
  Gao et al,[@b23-dddt-12-2173] 2017     S-1+apatinib                               S-1                               ND                  2015.6--2016.6       500--850 mg/time, 1 time/d
  Hu et al,[@b24-dddt-12-2173] 2016      S-1+apatinib                               S-1                               I                   2015.1--2016.8       800--850 mg/time, 1 time/d
  Jing,[@b25-dddt-12-2173] 2016          S-1+apatinib                               S-1                               I                   2014.11--2015.12     500 mg/time, 1 time/d
  Li et al,[@b26-dddt-12-2173] 2018      FOLFOX+apatinib                            FOLFOX                            ≥III                2014.12--2016.12     250--850 mg/time, 1 time/d
  Li and Li,[@b27-dddt-12-2173] 2017     Oxaliplatin+S-1+apatinib                   Oxaliplatin+S-1                   ≥III                2015.2--2016.2       850 mg/time, 1 time/d
  Li,[@b28-dddt-12-2173] 2017            FBC+apatinib                               Fluorouracil                      ND                  ND                   250 mg/time, 1 time/d
  Qian and Ge,[@b29-dddt-12-2173] 2017   Taxanes/platinum/fluorouracil+apatinib     Taxanes/platinum/fluorouracil     ND                  2015.6--2017.6       500 mg/time, 1 time/d
  Sheng et al,[@b30-dddt-12-2173] 2017   S-1+apatinib                               S-1                               II                  ND                   250 mg/time, 2 times/d
  Wang et al,[@b31-dddt-12-2173] 2016    S-1+apatinib                               S-1                               ND                  2015.2--2016.6       850 mg/time, 1 time/d
  Wen et al,[@b32-dddt-12-2173] 2017     Oxaliplatin+S-1+apatinib                   Oxaliplatin+S-1                   ND                  2014.1--2016.4       850 mg/time, 1 time/d
  Wu et al,[@b33-dddt-12-2173] 2017      S-1+apatinib                               S-1                               II                  2015.12--2017.2      500 mg/time, 1 time/d
  Yan et al,[@b34-dddt-12-2173] 2017     Oxaliplatin+S-1+apatinib                   Oxaliplatin+S-1                   ≥III                2015.3--2017.3       850 mg/time, 1 time/d
  Zhan,[@b35-dddt-12-2173] 2017          FOLFIRI+apatinib                           FOLFIRI                           ND                  2011.5--2013.5       425--850 mg/d, 1 time/d
  Zhou et al,[@b36-dddt-12-2173] 2018    S-1+apatinib                               S-1                               ≥II                 2015.7--2016.10      850 mg/time, 1 time/d
  Zhu et al,[@b37-dddt-12-2173] 2016     Taxanes/irinotecan/fluorouracil+apatinib   Taxanes/irinotecan/fluorouracil   ND                  2014.7--2016.7       500 mg/time, 1 time/d

**Notes:** Con, control group (CT alone group); Exp, experimental group (apatinib targeted therapy plus CT).

**Abbreviations:** CT, chemotherapy; FBC, fluorouracil-based chemotherapy; FOLFIRI, calcium folinate+irinotecan+5-fluorouracil; FOLFOX, oxaliplatin+calcium folinate+ 5-fluorouracil; ND, not determined; S-1, gimeracil and oteracil porassium capsules.

###### 

Comparison of CR, PR, SD, PD, ORR, and DCR between the experimental and control groups

  Parameter   Exp   Con   Analysis method   Heterogeneity   OR     95% CI   P-value      
  ----------- ----- ----- ----------------- --------------- ------ -------- ------------ -----------
  CR          625   631   Fixed             0               0.96   1.85     1.04--3.28   0.04
  PR          625   631   Fixed             0               0.89   2.19     1.71--2.80   \<0.00001
  SD          596   602   Fixed             0               0.59   1.09     0.86--1.39   0.48
  PD          596   602   Fixed             0               0.94   0.33     0.25--0.44   \<0.00001
  ORR         625   631   Fixed             0               1.00   2.57     1.99--3.32   \<0.00001
  DCR         596   602   Fixed             0               0.84   3.46     2.57--4.66   \<0.00001

**Notes:** Con, control group (CT alone group); Exp, experimental group (apatinib targeted therapy plus CT).

**Abbreviations:** CR, complete response rates; CT, chemotherapy; DCR, disease control rate; OR, odds ratio; ORR, overall response rate; PD, progressive disease rates; PR, partial response rates; SD, stable disease rates.

###### 

Comparison of AEs between the experimental and control groups

  AEs                    Exp   Con   Analysis method   Heterogeneity   OR      95% CI   *P*-value     
  ---------------------- ----- ----- ----------------- --------------- ------- -------- ------------- -----------
  Leukopenia             123   118   Fixed             0               0.67    1.73     0.96--3.10    0.07
  Thrombocytopenia       244   239   Fixed             0               0.91    1.31     0.79--2.18    0.29
  Diarrhea               252   251   Fixed             0               0.75    0.63     0.36--1.10    0.10
  Nausea, vomiting       348   355   Fixed             25              0.21    1.02     0.71--1.46    0.92
  Hypertension           392   395   Random            60              0.005   5.75     2.22--14.92   0.0003
  Neutropenia            120   120   Fixed             0               0.83    1.33     0.68--2.59    0.40
  Albuminuria            175   182   Fixed             0               0.62    15.42    5.39--44.10   \<0.00001
  Oral mucositis         274   281   Fixed             33              0.16    1.19     0.80--1.77    0.40
  Hand--foot syndrome    262   257   Fixed             0               0.57    2.09     1.26--3.48    0.004
  Weak                   209   208   Fixed             0               0.58    1.09     0.70--1.70    0.70
  Hemoglobin reduction   77    72    Random            55              0.08    2.13     0.69--6.59    0.19
  Myelosuppression       129   137   Fixed             0               0.79    0.96     0.57--1.63    0.89

**Notes:** Con, control group (CT alone group); Exp, experimental group (apatinib targeted therapy plus CT).

**Abbreviations:** AE, adverse event; CT, chemotherapy; OR, odds ratio.

###### 

Subgroup analyses of ORR and DCR between the experimental and control groups

  Parameter                    Factors at study level    Exp   Con     Analysis method   Heterogeneity   OR     95% CI        *P*-value   
  ---------------------------- ------------------------- ----- ------- ----------------- --------------- ------ ------------- ----------- --
  ORR                          **Therapeutic regimen**                                                                                    
  Apatinib+FOLFOX              66                        58    Fixed   0                 0.66            2.63   1.24--5.56    0.01        
  Apatinib+S-1+oxaliplatin     155                       155   Fixed   0                 0.91            2.42   1.46--4.01    0.0006      
  Apatinib+FBC                 60                        60    Fixed   0                 0.35            2.58   1.24--5.39    0.01        
  Apatinib+S-1                 197                       196   Fixed   0                 1.00            2.40   1.51--3.82    0.0002      
  **Dosage of apatinib**                                                                                                                  
  850 mg/d                     236                       232   Fixed   0                 1.00            2.29   1.53--3.43    \<0.0001    
  500 mg/d                     215                       230   Fixed   0                 0.84            3.07   1.94--4.88    \<0.00001   
  **Study sample size**                                                                                                                   
  .50                          496                       503   Fixed   0                 0.96            2.52   1.89--3.37    \<0.00001   
  \<50                         129                       128   Fixed   0                 0.97            2.75   1.57--4.79    0.0004      
  **Type of control trials**                                                                                                              
  RCT                          450                       445   Fixed   0                 1.00            2.38   1.77--3.22    \<0.00001   
  Non-RCT                      175                       186   Fixed   0                 0.68            3.16   1.92--5.20    \<0.00001   
  DCR                          **Therapeutic regimen**                                                                                    
  Apatinib+FOLFOX              66                        58    Fixed   0                 0.67            6.74   2.07--21.95   0.002       
  Apatinib+S-1+oxaliplatin     155                       155   Fixed   0                 0.49            3.07   1.89--5.00    \<0.00001   
  Apatinib+FBC                 60                        60    Fixed   0                 0.73            8.80   2.45--31.70   0.0009      
  Apatinib+S-1                 168                       167   Fixed   0                 0.63            2.78   1.51--5.10    0.0010      
  **Dosage of apatinib**                                                                                                                  
  850 mg/d                     207                       203   Fixed   0                 0.79            3.21   2.03--5.07    \<0.00001   
  500 mg/d                     215                       230   Fixed   0                 0.43            3.32   2.02--5.48    \<0.00001   
  **Study sample size**                                                                                                                   
  \>50                         467                       474   Fixed   0                 0.61            3.43   2.45--4.79    \<0.00001   
  \<50                         129                       128   Fixed   0                 0.78            3.58   1.86--6.90    0.0001      
  **Type of control trials**                                                                                                              
  RCT                          421                       416   Fixed   0                 0.89            2.88   1.98--4.18    \<0.00001   
  Non-RCT                      175                       186   Fixed   0                 0.68            4.79   2.89--7.92    \<0.00001   

**Notes:** Con, control group (CT alone group); Exp, experimental group (apatinib targeted therapy plus CT).

**Abbreviations:** CI, confidence interval; CT, chemotherapy; DCR, disease control rate; FBC, fluorouracil-based chemotherapy; FOLFOX, oxaliplatin+calcium folinate+5-fluorouracil; OR, odds ratio; ORR, overall response rate; QIR, quality of life improved rate; RCT, randomized controlled trial; S-1, gimeracil and oteracil porassium capsules.
